- Home
- ACLX vs HALO Comparison
ACLX vs HALO Comparison
Compare ACLX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- HALO
- Stock Information
- Founded
- ACLX 2015
- HALO 1998
- Country
- ACLX United States
- HALO United States
- Employees
- ACLX N/A
- HALO N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLX Health Care
- HALO Health Care
- Exchange
- ACLX Nasdaq
- HALO Nasdaq
- Market Cap
- ACLX 5.3B
- HALO 6.4B
- IPO Year
- ACLX 2022
- HALO N/A
- Fundamental
- Price
- ACLX $79.13
- HALO $47.74
- Analyst Decision
- ACLX Strong Buy
- HALO Buy
- Analyst Count
- ACLX 14
- HALO 9
- Target Price
- ACLX $107.67
- HALO $61.11
- AVG Volume (30 Days)
- ACLX 601.0K
- HALO 1.3M
- Earning Date
- ACLX 02-26-2025
- HALO 02-18-2025
- Dividend Yield
- ACLX N/A
- HALO N/A
- EPS Growth
- ACLX N/A
- HALO 61.71
- EPS
- ACLX N/A
- HALO 3.02
- Revenue
- ACLX $155,818,000.00
- HALO $947,355,000.00
- Revenue This Year
- ACLX $12.58
- HALO $23.36
- Revenue Next Year
- ACLX N/A
- HALO $15.35
- P/E Ratio
- ACLX N/A
- HALO $15.79
- Revenue Growth
- ACLX 230.33
- HALO 21.35
- 52 Week Low
- ACLX $47.88
- HALO $33.15
- 52 Week High
- ACLX $107.37
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- ACLX 44.15
- HALO 45.09
- Support Level
- ACLX $75.60
- HALO $46.26
- Resistance Level
- ACLX $79.50
- HALO $49.00
- Average True Range (ATR)
- ACLX 3.65
- HALO 1.23
- MACD
- ACLX 0.20
- HALO 0.22
- Stochastic Oscillator
- ACLX 41.95
- HALO 44.31
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.